{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-22-000028","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.546145+00:00","generated_at":"2026-06-22T11:50:03.863771+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"United Therapeutics Q3 revenue $516M (+16% YoY); net income $239M (+47%)","bullets":["Net income per diluted share $4.91; Tyvaso revenues $257.7M (+57% YoY) driven by Tyvaso DPI launch.","Tyvaso achieved $1B annual run-rate; management targets 6,000 patients on Tyvaso by year-end.","R&D expense $66.1M (-17% YoY) due to fair value adjustments; PERFECT study discontinued per DSMC.","TETON 2 study of Tyvaso in IPF enrolled first patient October 2022; TETON 1 enrollment ongoing.","Remunity Pump launched patient-filled version in September 2022 for monthly cassette shipments."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-22-000028","json":"https://secwatch.observer/filing/0001082554-22-000028.json","markdown":"https://secwatch.observer/filing/0001082554-22-000028.md","text":"https://secwatch.observer/filing/0001082554-22-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000028/0001082554-22-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000028/uthr-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T11:50:03.863771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bc8b4333ecc6c401175789877cb202ccdca7b76","claim":"UNITED THERAPEUTICS Corp reported the quarter ended September 30, 2022 results: revenue $516.0 million, net income $239.3, EPS $4.91.","evidence_excerpt":"benefit corporation, today announced its financial results for the quarter ended September 30, 2022. Total revenues in the third quarter of 2022 grew 16% year-over-year to $516.0 million, compared to $444.7 million in the third quarter of 2021. “We are thrilled to report the highest quarterly revenue in our history,” said Martine Rothblatt, Ph.D. , Chairperson","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000028/0001082554-22-000028-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$516.0 million"},{"label":"Net income","value":"$239.3"},{"label":"EPS","value":"$4.91"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}